Drug Pricing Push: President Trump announced “most-favored-nation” Medicaid pricing deals with nine more pharma companies, bringing the total to 26 and claiming coverage for 89% of brand-name drugs, though deal terms weren’t released publicly. HIV Treatment Update: The FDA approved Gilead’s Bixlenvo (bictegravir/lenacapavir) as a once-daily switch regimen for virologically suppressed adults, with eligibility tied to no known resistance. Women’s Health Naming Shift: A new clinical discussion explains the move from PCOS to PMOS and why clinicians may need to refocus on lifelong metabolic risk, not just reproductive concerns. Access & Coverage Pressure: A Senate report from Sen. Jon Ossoff accuses insurers of delaying or denying care via prior authorization, highlighting patient harm and financial distress. Local Care Expansion: Health First plans Brevard’s first freestanding ER in Rockledge and touts Viera Hospital’s statewide quality recognition. Global Health Funding: An analysis says secretive U.S. bilateral health agreements could cut global aid by tens of billions by 2030. Medical Tourism Watch: South Korea reports a 66.5% jump in foreign spending on medical services in July, led by dermatology and plastic surgery. Aging Demographics: A Census Bureau report projects the world’s 65+ population nearly doubling by 2060, reshaping health systems worldwide. Mental Health & Recovery: Victory Recovery Partners will open a licensed outpatient substance use and mental health center in Hauppauge this fall. Tech in Care: Cleveland Clinic describes AI-assisted prostate cancer MRI interpretation to speed decisions and guide biopsies.